Oxford Biomedica plc (LON:OXB)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 516.23M -21.3% |
| Revenue (ttm) | 168.74M +31.0% |
| Net Income | -30.13M |
| EPS | -0.27 |
| Shares Out | 121.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 430.50 |
| Previous Close | 426.50 |
| Day's Range | 420.00 - 435.00 |
| 52-Week Range | 420.00 - 962.00 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 712.00 (+63.68%) |
| Earnings Date | Sep 22, 2026 |
About Oxford Biomedica
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary ‘plug and play’ dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical an... [Read more]
Financial Performance
In 2025, Oxford Biomedica's revenue was 168.74 million, an increase of 31.01% compared to the previous year's 128.80 million. Losses were -30.13 million, -30.24% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for OXB stock is "Buy." The 12-month stock price target is 712p, which is an increase of 63.68% from the latest price.
News
Oxford Biomedica downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Oxford Biomedica (OXBDF) to Hold from Buy with a price target of 595 GBp, down from 800 GBp. The firm cites slower revenue conversion and program delays…
Oxford Biomedica downgraded to Hold from Buy at Investec
Investec analyst Jens Lindqvist downgraded Oxford Biomedica (OXBDF) to Hold from Buy with a 508 GBp price target
Oxford Biomedica price target lowered to 900 GBp from 1,140 GBp at RBC Capital
RBC Capital lowered the firm’s price target on Oxford Biomedica (OXBDF) to 900 GBp from 1,140 GBp and keeps an Outperform rating on the shares.
UK's Oxford Biomedica tumbles after annual revenue forecast cut
Britain's Oxford Biomedica fell more than 24% on Friday after the cell and gene therapy manufacturer cut its 2026 revenue forecast, citing operational delays at a U.S. site and deferred client order...
UK Stock Market News: Stelrad, Vaalco Energy, Oxford Biomedica
Lower revenues but higher margins at Stelrad, Vaalco Energy sees production improvement, revenues grow at Oxford Biomedica
Oxford Biomedica Earnings release: H1 2026
Oxford Biomedica released its H1 2026 earnings on August 7, 2026, summarizing the period's financial results.
Oxford Biomedica price target lowered to 1,140 GBp at RBC Capital
RBC Capital analyst Charles Weston lowered the firm’s price target on Oxford Biomedica (OXBDF) to 1,140 GBp from 1,170 GBp and keeps an Outperform rating on the shares. Published first…
Oxford Biomedica Slides: Investor presentation
Oxford Biomedica has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
Oxford Biomedica Earnings Call Transcript: H2 2025
Revenue grew 33% year-over-year to GBP 170.9 million, with first full year of EBITDA profitability and strong cash position. U.S. expansion, a robust order backlog, and multi-vector capabilities support above-market growth targets for 2026 and beyond.
Oxford Biomedica Annual report: H2 2025
Oxford Biomedica has published its H2 2025 annual report on March 26, 2026.
Oxford Biomedica Annual report: H2 2025
Oxford Biomedica has published its H2 2025 annual report on March 26, 2026.
Oxford Biomedica Slides: H2 2025
Oxford Biomedica has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 26, 2026.
Oxford Biomedica resumed with a Buy at Jefferies
Jefferies resumed coverage of Oxford Biomedica (OXBDF) with a Buy rating and 827 GBp price target. The firm sees the company entering “a more profitable phase” and sees the Bristol…
EQT backs out of takeover bid for UK's Oxford Biomedica
Private equity group EQT said on Wednesday it had decided not to proceed with a takeover offer for Oxford Biomedica , sending the British cell and gene therapy manufacturer's shares down nearly 10%.
Oxford Biomedica sees FY25 revenue GBP 166M -GBP 169M
FY 2025 Operating EBITDA profitability expected to be mid-to-high single-digit GBP million including a larger than expected non-recurring gain from the Durham, NC acquisition; excluding the impact of ...
Oxford Biomedica sees FY26 revenue GBP 220M -GBP 240M
Reflecting increasing demand for OXB’s services, the contracted value of client orders reached GBP 224 million for the year ended 31 December 2025, an increase of 20% compared to GBP…
UK's Oxford Biomedica confirms unsolicited bid from funds managed by EQT
British cell and gene therapy manufacturer Oxford Biomedica confirmed on Wednesday that it has received an unsolicited cash offer from funds managed by EQT for all of its shares.
Oxford Biomedica upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Oxford Biomedica (OXBDF) to Buy from Hold with a price target of 735 GBp, up from 380 GBp. The firm sees a higher-quality business following the company’s…
Oxford Biomedica upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Oxford Biomedica (OXBDF) to Buy from Hold with a price target of 735 GBp, up from 380 GBp.
Oxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorgan
JPMorgan raised the firm’s price target on Oxford Biomedica (OXBDF) to 550 GBp from 400 GBp and keeps a Neutral rating on the shares.
Oxford Biomedica Transcript: Jefferies London Healthcare Conference 2025
A focused CDMO in Cell and Gene Therapy reported strong order growth, expanded U.S. operations with a new Durham facility, and enhanced financial flexibility. Innovation and operational improvements support ambitious revenue and profitability targets for 2025–2028.
Oxford Biomedica Transcript: Stifel 2025 Healthcare Conference
A global CDMO specializing in viral vectors for cell and gene therapy is expanding its US and EU footprint, achieving strong revenue growth and targeting 25–30% annual growth through 2028. Recent investments and acquisitions support capacity, while innovation and expertise drive competitive advantage.
Oxford Biomedica says existing financial guidance ‘remains unchanged’
The Company’s existing financial guidance remains unchanged, with the acquisition supporting OXB’s long-term top-line growth outlook and existing near and medium-term financial guidance. The Company e...
Oxford Biomedica price target raised to 970 GBp from 930 GBp at RBC Capital
RBC Capital raised the firm’s price target on Oxford Biomedica (OXBDF) to 970 GBp from 930 GBp and keeps an Outperform rating on the shares.
Oxford Biomedica Earnings Call Transcript: H1 2025
H1 2025 saw 44% revenue growth and a 166% rise in contracted orders, with profitability improving and a strengthened balance sheet. Strategic investments and a robust pipeline support guidance for sustained double-digit growth and margin expansion through 2028.